Introduction
GSK plc (LSE:GSK) is attempting to reshape how eligible severe-asthma patients are treated by moving from monthly or two-monthly injections towards a maintenance schedule of just two doses a year. Its biologic Exdensur (depemokimab) is an ultra-long-acting anti-interleukin-5 (IL-5) monoclonal antibody designed for subcutaneous administration approximately once every six months.
The central question for investors is what this twice-yearly model could mean commercially. The theory is straightforward: fewer clinic visits and fewer injections may appeal to patients and prescribers. Depemokimab is approved for severe or eosinophilic asthma in adults and adolescents aged 12 and older in the UK (15 December 2025), the US (16 December 2025) and the EU (17 February 2026).
Yet convenience is not the same as success. Lower dosing frequency does not automatically deliver better adherence, outcomes or sales, and a US regulatory setback for the nasal-polyps indication complicates the picture. This article examines the evidence, the delivery implications, the competition and the risks.
What is depemokimab and who owns it?
Depemokimab, marketed as Exdensur (in the US, depemokimab-ulaa), is a humanised anti-IL-5 monoclonal antibody of the IgG1 kappa class. IL-5 is a key signalling protein that drives the production, activation and survival of eosinophils, a type of white blood cell central to type 2 inflammatory disease. By binding circulating IL-5 with high affinity, depemokimab blocks that signalling and reduces eosinophil activity.
What distinguishes it mechanistically is engineering for an extended half-life. According to GSK, high binding affinity combined with this extended half-life is what enables a twice-yearly subcutaneous maintenance schedule rather than the more frequent dosing typical of the anti-IL-5 class.
Exdensur is a wholly GSK-developed and GSK-owned biologic, with no joint venture or in-licence disclosed. GSK plc holds the marketing authorisations directly, and in the US the biologics licence application (BLA 761458) is held via subsidiary GlaxoSmithKline LLC. It is positioned as the successor long-acting anti-IL-5 asset to GSK's own mepolizumab (Nucala), and is not a ViiV or Haleon asset.
It is worth noting that the presence of a substance in a regulatory index only evidences that product files exist. It is not, by itself, proof of new approval, ownership, launch timing or commercial success; those rest on the specific regulatory decisions described here.
What is the proposed or approved dosing schedule?
Depemokimab is approved for a maintenance schedule of one subcutaneous dose approximately every six months, that is, twice yearly. This is the defining feature of the product and the basis of GSK's differentiation argument within the respiratory-immunology franchise.
For context, existing anti-IL-5 and related type 2 biologics are generally administered far more frequently, ranging from every four weeks to every eight weeks depending on the product and indication. A shift to two administrations per year represents a substantial reduction in the number of scheduled dosing events for eligible patients.
The dosing model is now an approved, marketed reality for asthma rather than an investigational proposal, following authorisations in the UK, US and EU. Where the term investigational still applies is in markets where filings remain under review, and in the US for the nasal-polyps indication, which has not been approved.
What clinical evidence supports it?
The registrational evidence for the asthma indication came principally from the phase III SWIFT-1 and SWIFT-2 trials, results from which were presented and published in September 2024. GSK has reported that these studies showed a significant reduction in asthma exacerbations with twice-yearly depemokimab, and this data set underpinned the regulatory filings.
For chronic rhinosinusitis with nasal polyps (CRSwNP), the supporting phase III programme comprised the ANCHOR-1 and ANCHOR-2 trials. Specific efficacy percentages are not restated here to avoid misrepresenting the trial results; readers should refer to the approved product information and peer-reviewed publications for precise endpoints.
Regulators in three regions judged the overall evidence sufficient to approve the asthma indication. The EMA's CHMP adopted a positive opinion at its 8-11 December 2025 meeting, preceding the European Commission decision by roughly two months. Clinical results suggest the twice-yearly schedule can maintain disease control in appropriately selected patients, though long-term real-world durability of a fixed six-monthly biologic remains an area to monitor.
How could lower dosing frequency affect treatment delivery?
A twice-yearly schedule could, in principle, reduce the burden associated with severe-asthma biologic therapy. Fewer scheduled doses may mean fewer clinic or pharmacy visits and fewer injections over a year, which some patients and healthcare systems may value.
For health services, less frequent administration could ease scheduling and free capacity, particularly where biologics are administered in a clinical setting. It may also simplify the logistics of long-term maintenance for stable patients. These are potential operational benefits rather than guaranteed ones.
However, the mandatory caution applies firmly here: reduced dosing frequency does not automatically produce better adherence or clinical outcomes. Missing a twice-yearly dose leaves a longer coverage gap, and prescribers may weigh the reduced flexibility of a fixed six-monthly regimen against its convenience. The real-world value of the delivery model will depend on how patients, clinicians and payers respond in practice.
What competing biologics are available?
The type 2 and eosinophilic asthma biologic market is competitive and well established. Within the anti-IL-5 pathway, GSK's own mepolizumab (Nucala) is dosed monthly or every eight weeks, AstraZeneca's benralizumab (Fasenra) targets the IL-5 receptor alpha, and Teva's reslizumab (Cinqair/Cinqaero) is a further anti-IL-5 option.
Beyond the IL-5 axis, dupilumab (Dupixent) from Sanofi and Regeneron targets IL-4 receptor alpha and is used in both severe asthma and CRSwNP. AstraZeneca and Amgen's tezepelumab (Tezspire), an anti-TSLP antibody, addresses severe asthma across inflammatory phenotypes, while Novartis and Genentech's omalizumab (Xolair) targets IgE in allergic asthma and nasal polyps.
Against this field, depemokimab's principal differentiator is dosing convenience rather than a claimed efficacy advantage over rivals. Notably, its closest internal comparator is GSK's own Nucala, which introduces a cannibalisation dynamic: uptake of Exdensur may come partly at the expense of GSK's existing anti-IL-5 franchise rather than purely from new patients.
What access and adherence considerations remain?
Market access will be a decisive factor. In the UK and EU, uptake will depend in part on health technology assessment and reimbursement outcomes, including any NICE appraisal, which can shape both the eligible population and the pace of adoption. Reimbursement and HTA risk is a recognised principal risk for the product.
On adherence, the intuitive appeal of fewer injections must be tested against clinical reality. It cannot be assumed that a twice-yearly schedule will improve persistence; some patients may value more frequent contact with clinicians, and the consequences of a delayed or missed six-monthly dose differ from those of a shorter cycle.
Patient selection also matters. The approved asthma indication is restricted to those aged 12 and older with type 2 inflammation of an eosinophilic phenotype who are inadequately controlled on maximum inhaled corticosteroids plus another controller. The CRSwNP indication, where approved, is limited to adults with severe disease inadequately controlled by systemic corticosteroids and/or surgery.
The US nasal-polyps setback and regulatory divergence
A critical nuance for investors is that the three regions diverge on the nasal-polyps indication. The UK MHRA (15 December 2025) and the European Commission (17 February 2026) approved Exdensur for both severe/type 2 eosinophilic asthma and CRSwNP.
The US FDA, however, approved depemokimab-ulaa on 16 December 2025 for severe eosinophilic asthma only. It issued a Complete Response Letter for the CRSwNP indication, which is therefore not approved in the US. GSK has confirmed it remains in active dialogue with the FDA.
This divergence narrows the near-term addressable US market relative to the UK and EU and is a clear principal risk. The asthma opportunity is intact across all three regions, but the US nasal-polyps pathway carries execution uncertainty. Investors may monitor any further FDA communications on this indication.
What could the product mean for GSK's respiratory growth?
GSK positions depemokimab within its Specialty Medicines and respiratory-immunology franchise as a next-generation, twice-yearly successor to Nucala. The strategic logic is to extend the company's anti-IL-5 leadership with a differentiated dosing profile as older products face lifecycle pressures.
The addressable population, severe and eosinophilic asthma patients inadequately controlled on standard therapy, is meaningful, and the potential for nasal-polyps use in the UK and EU adds breadth. However, no product-level Exdensur revenue is separately disclosed in GSK reporting given the December 2025 and February 2026 launch timing; any figure would be pre- or early-launch, so none is stated here. Market-share and peak-sales forecasts are likewise not drawn from primary GSK disclosure.
Growth drivers could include the convenience proposition, breadth of approved indications outside the US, and GSK's established respiratory commercial infrastructure. Commercial performance will depend on reimbursement, prescriber adoption, competitive response and real-world durability. Principal risks include the US CRSwNP CRL, Nucala cannibalisation, intense class competition, HTA outcomes, long-term safety and efficacy in real-world use, and regulatory execution on outstanding filings in markets such as China and Japan.
Investors may monitor NICE and other HTA decisions, any resolution of the US nasal-polyps CRL, and the first disclosures of launch traction in GSK's financial reporting. Information verified as at 14 July 2026, 5:00 pm (UK time, BST).
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...